Table 5b lists OPO code NJTO with a CY2021 Tier Status of 2 (Tier 2); the 2019 and 2020 statuses had been 1.
This OPO is graded Tier 2 (2023 Assessment (CY2021 data)) under the CMS Conditions for Coverage outcome measures. Tier 2 is above the median but below the top quartile; these OPOs must compete to retain their service area.
Whistleblowers and congressional oversight expanded to a New Jersey OPO
U.S. House Ways and Means Committee; New Jersey Organ and Tissue Sharing Network (New Jersey Sharing Network)
In a follow-up letter dated November 19, 2025, the House Ways and Means Committee stated that nearly a dozen whistleblowers had come forward alleging patient-safety violations at the New Jersey Organ and Tissue Sharing Network, including allegations that staff pressured a hospital to proceed with a DCD donation after a patient showed signs of life during the recovery process, and that case documentation may have been deleted or manipulated. The Committee said the concerns indicated DCD safety issues extended beyond a single OPO.
OPOs hold board seats and reported financial stakes in tissue processors (per reform-group analysis of OPO 990s)
AlloSource board (executives from Donor Alliance, Iowa Donor Network, Mid-America Transplant, ConnectLife, Gift of Hope); MTF Biologics board (Midwest Transplant Network, LifeShare of Oklahoma, New Jersey Sharing Network)
A published analysis by Organ Donation Reform (costlyeffects.organdonationreform.org), citing the OPOs' own IRS Form 990 filings on ProPublica, states that executives from five named OPOs sit on AlloSource's board and that these OPOs hold ownership stakes in AlloSource ranging from $8 million to $26.4 million, and that executives from three additional named OPOs sit on the MTF Biologics board. This is an advocacy-group compilation derived from public 990 data, not a government finding; the underlying per-OPO 990 figures should be independently confirmed.
Every item is institution-level public record, source-linked; no patient, donor, or family is named. A Tier or finding here repeats the government's own assessment of an organization holding a public monopoly. Back to OrganWatch.